Related by context. All words. (Click for frequent words.) 72 urothelial carcinoma 72 ovarian carcinoma 72 prostate carcinoma 71 nonmetastatic 71 pancreatic adenocarcinoma 71 primary hyperparathyroidism 71 metaplasia 71 liver histology 70 urothelial cancer 70 epithelial tumors 70 metastatic malignant 69 leukemia AML 69 gastric carcinoma 69 renal cell carcinomas 69 prostate adenocarcinoma 69 T1a 69 pT2 69 breast carcinoma 69 NMIBC 69 colorectal carcinoma 68 HER2 overexpression 68 colorectal liver metastases 68 Histological 68 idiopathic myelofibrosis 68 nonalcoholic steatohepatitis NASH 68 MGUS 68 SSc 68 sarcomatoid 68 monoclonal gammopathy 68 gastric adenocarcinoma 68 recurrent glioblastoma multiforme 68 hepatocellular carcinomas 68 metastatic gastric 68 ADPKD 68 prostate cancer CaP 68 Leydig cell 68 microsatellite instability 68 cranial irradiation 68 histological subtype 67 pretransplant 67 histologic subtype 67 leiomyomas 67 papillary renal cell carcinoma 67 atypical hemolytic uremic syndrome 67 haematologic 67 completely resected 67 relapsed MM 67 Myelodysplastic Syndrome MDS 67 Papillary 67 ara C 67 basal cell carcinoma BCC 67 visceral metastases 67 mucinous 67 malignant lymphomas 67 HBeAg 67 thyroid carcinoma 67 LHRH receptor positive 67 operable breast cancer 67 prognostic indicator 67 abacavir Ziagen 67 bronchogenic carcinoma 67 locoregional recurrence 67 genotypic resistance 67 mutated K ras 67 colorectal adenoma 67 biochemical relapse 67 Hurthle cell 66 GISTs 66 undetectable HBV DNA 66 AA Amyloidosis 66 metastatic neuroendocrine tumors 66 PCa 66 HSCT 66 cervical carcinoma 66 histologically confirmed 66 Leukemias 66 biliary tract cancer 66 hepatoma 66 T1c 66 Follicular Lymphoma 66 liver metastasis 66 neoplasias 66 Chronic lymphocytic leukemia 66 TIMP 66 urothelial bladder cancer 66 myelodysplastic myeloproliferative diseases 66 euthymic patients 66 malignant lymphoma 66 ERalpha 66 urothelial 66 B Cell Lymphoma 66 Lenalidomide 66 Estrogen Receptor 66 HER2 expression 66 gastrointestinal stromal tumor GIST 66 MGd 66 paraganglioma 66 cytoreduction 66 underwent resection 66 Acute Myeloid Leukaemia AML 66 Retreatment 66 taxane refractory 66 pancreatic ductal adenocarcinoma 66 Antiviral Therapy 66 refractory ovarian cancer 66 prospectively enrolled 66 de novo AML 66 cholangiocarcinoma 66 Non Alcoholic Steatohepatitis 65 posttransplant 65 IPAH 65 null responder 65 surgically resectable 65 haematopoietic 65 node metastases 65 metachronous 65 Glioblastoma Multiforme 65 Doxil ® 65 hepatic metastasis 65 Atypical Hemolytic Uremic Syndrome 65 clinicopathological features 65 ABL1 65 hepatic metastases 65 gastrointestinal stromal tumors GIST 65 metastatic malignant melanoma 65 urolithiasis 65 grade cervical intraepithelial 65 thymoma 65 Surgical resection 65 stage IIIB 65 μmol L 65 situ CIS 65 complement inhibitor eculizumab 65 malignant pleural mesothelioma 65 hypereosinophilic syndrome 65 cervical intraepithelial neoplasia 65 ErbB2 positive 65 pulmonary metastases 65 peritoneal carcinomatosis 65 neoplasm 65 CIN2 + 65 HNSCC 65 allogeneic HSCT 65 clinicopathological 65 demonstrated antitumor activity 65 external beam radiotherapy 65 mediated inhibition 65 LV dysfunction 65 hepatorenal syndrome 65 hypercalciuria 65 deletion 5q 65 squamous cell carcinoma SCC 65 BRAF V#E mutation 65 Naive Patients 65 haematological cancers 65 HGPIN 65 metastatic renal cell carcinoma 65 unresectable tumors 65 kinase inhibition 65 reflux esophagitis 65 HeFH 65 Legg Calvé Perthes disease 65 bone scintigraphy 65 HepG2 cells 65 CP CPPS 65 NNRTI resistance 65 CTEPH 64 metastatic bladder 64 situ LCIS 64 Natalizumab 64 chronic eosinophilic leukemia 64 Macrophage 64 cisplatin gemcitabine 64 Tyrosine Kinase Inhibitors 64 localized renal 64 serous ovarian cancer 64 prostate cancer PCa 64 Decitabine 64 missense mutations 64 intraepithelial neoplasia 64 pegylated liposomal doxorubicin 64 ABCB1 64 Hodgkin lymphoma HL 64 histologically proven 64 allogeneic hematopoietic stem cell 64 biochemical recurrence 64 adenomatous 64 ASCUS 64 lesional 64 refractory colorectal cancer 64 intestinal metaplasia 64 cisplatin resistant 64 androgen deprivation 64 Endometrial 64 p# biomarker 64 invasive candidiasis 64 redox active 64 trastuzumab Herceptin ® 64 Adjuvant chemotherapy 64 invasive aspergillosis 64 carcinoembryonic antigen 64 Acute myeloid leukemia 64 acute myeloid 64 PCNSL 64 graft dysfunction 64 breast carcinomas 64 radiotherapy RT 64 thrombocytopenic 64 invasive carcinoma 64 CIN3 64 complete cytogenetic response 64 fallopian tube carcinoma 64 Nilotinib 64 pelvic lymphadenectomy 64 histologic findings 64 CLL SLL 64 alkylating agent 64 inhibitor RG# 64 pmol L 64 Idiopathic Pulmonary Fibrosis 64 CTAP# Capsules 64 H pylori 64 KRAS mutations 64 gene polymorphism 64 Haptoglobin 64 myeloproliferative diseases 64 prognostic biomarker 64 lobular carcinoma 64 interstitial fibrosis 64 T1DM 64 carcinoid tumors 64 mRCC 64 adjuvant radiotherapy 64 chemoradiation therapy 64 K ras mutations 64 undergoing radical cystectomy 64 pulmonary metastasis 64 idiopathic PAH 64 Squalamine 64 antiretroviral naïve 64 HER2 positive metastatic breast 64 bronchoalveolar lavage 64 lymph node dissection 64 interstitial brachytherapy 64 stratifying patients 64 polycythemia vera essential thrombocythemia 64 liposomal amphotericin B 64 diabetes mellitus DM 64 renal cysts 64 renal tumors 64 Immunohistochemical staining 64 decompensated cirrhosis 64 multiple myeloma MM 64 metastatic GIST 64 JMML 64 leukemia ALL 64 Adenomas 64 elevated LDH 64 immunostaining 64 superficial bladder cancer 64 COL#A# 64 non splenectomized 64 tiuxetan 64 ischemic mitral regurgitation 64 irreversible inhibitor 64 TNF Tumor Necrosis Factor 64 colon carcinoma 64 inducible nitric oxide synthase 64 somatostatin analog 64 SYN# 64 Platinol ® 64 Pegylated Interferon 64 MELAS 64 thalidomide Thalomid 64 Lymphocytic 64 malignant ascites 64 indolent lymphomas 64 ATTR CM 64 TOP2A gene 64 pCR 64 neoplastic cells 64 seropositivity 63 AGHD 63 carotid IMT 63 Clusterin 63 Allogeneic 63 Chronic Myelogenous Leukemia 63 thyroglobulin 63 gastrointestinal stromal tumors 63 basal cell nevus syndrome 63 taxane resistant 63 hepatic fibrosis 63 transplantation HCT 63 clinicopathologic 63 lymph node metastasis 63 femoral neck fracture 63 serum phosphate 63 CYT# potent vascular disrupting 63 thyroid peroxidase 63 chemoresistant 63 clinically localized prostate 63 metabolizer 63 TACE 63 intact parathyroid hormone 63 cytoreductive nephrectomy 63 receptor tyrosine kinase inhibitor 63 T#I [002] 63 Lymphoid 63 mycosis fungoides 63 taxane therapy 63 pT3 63 pleomorphic 63 oral squamous cell 63 TIMP 1 63 TPMT 63 BEXXAR Therapeutic Regimen 63 vWD 63 paragangliomas 63 neoadjuvant therapy 63 radiochemotherapy 63 tumoral 63 antiangiogenic agent 63 grade squamous intraepithelial 63 hyperoxaluria 63 neoplastic 63 antiphospholipid syndrome 63 pituitary adenomas 63 leiomyoma 63 immunohistochemical 63 transthyretin amyloidosis 63 seminoma 63 renal carcinoma 63 HCV Genotype 63 essential thrombocythemia 63 Neovascular Age Related Macular 63 bronchoalveolar lavage fluid 63 cytokeratin 63 relapsed AML 63 preoperative chemotherapy 63 radioiodine therapy 63 astrocytomas 63 tuberous sclerosis TS 63 neoadjuvant treatment 63 invasive lobular 63 Fludarabine 63 surgically resected 63 cTnI 63 antiangiogenic therapy 63 Myelofibrosis 63 % CI #.#-#.# [003] 63 prognostic indicators 63 SGPT 63 hematopoietic cancers 63 relapsing remitting MS RRMS 63 Gastrointestinal Stromal Tumors 63 enteroviral 63 neurological manifestations 63 KRAS mutation 63 osteoporotic vertebral compression fractures 63 pan HDAC inhibitor 63 tumor histology 63 resectable 63 Systemic Lupus Erythematosus SLE 63 trans retinoic acid 63 Adjuvant therapy 63 PNET 63 euthyroid 63 CC genotype 63 radical prostatectomy RP 63 Histologic 63 endocrine therapies 63 haematological malignancies 63 metastatic lymph nodes 63 abnormal cytology 63 HIV HCV coinfected 63 Microalbuminuria 63 combination antiretroviral therapy 63 gastrointestinal stromal tumors GISTs 63 syngeneic 63 Multiple Myeloma MM 63 pediatric acute lymphoblastic 63 choroidal neovascularization 63 immunomodulation 63 smoldering myeloma 63 tumors GIST 63 erlotinib Tarceva ® 63 refractory acute myeloid 63 endothelial activation 63 Cardiotoxicity 63 ELACYT 63 antimetabolite 63 F FDG PET 63 nodal metastasis 63 HBeAg negative 63 haematopoietic stem cell 63 posttreatment 63 pancreatic carcinoma 63 clinically detectable 63 macroalbuminuria 63 bevacizumab Avastin ® 63 advanced adenoma 63 hepatic encephalopathy HE 63 colorectal adenocarcinoma 63 5-fluorouracil/leucovorin 63 relapsed ALL 63 alanine aminotransferase ALT 63 total thyroidectomy 63 Kinoid 63 esophageal carcinoma 63 secondary hyperparathyroidism 63 polycystic kidneys 63 Mitomycin C 63 tumor necrosis 63 Soft Tissue Sarcoma 63 unfavorable cytogenetics 63 Chronic Prostatitis 63 neoadjuvant 63 cytoreductive surgery 63 chronic periodontitis 63 PDGFR 63 Leydig cells 63 fludarabine cyclophosphamide 63 CR nPR 63 imatinib resistance 63 Bezielle 63 sorafenib Nexavar 63 refractory metastatic 63 Cloretazine 63 medically inoperable 63 recurrent ovarian 63 Beta Amyloid 63 lactate dehydrogenase LDH 63 overt nephropathy 63 epithelioid 63 Pharmacokinetics PK 63 acute GvHD 63 hepatocellular carcinoma HCC 63 glioblastoma multiforme GBM 63 Immunohistochemical analysis 63 Severe Primary IGFD 63 diagnostic biomarker 63 myeloablative 63 adjuvant cisplatin 63 ß blockers 63 antiphospholipid antibodies 63 pheochromocytoma 63 alkaline phosphatase ALP 63 bacterial prostatitis 63 Pegylated 63 colorectal neoplasms 63 nutlin 3a 63 Chronic Myeloid Leukemia 63 follicular lymphoma FL 63 Sjögren syndrome 63 bladder ovarian 63 thrombocytosis 63 refractory AML 63 virological response 63 intrahepatic 63 castrate resistant prostate cancer 63 KRAS mutations occur 63 metalloproteinase 63 hematological relapse 63 transgenic rats 62 metastatic lesions 62 serum selenium 62 Trastuzumab 62 Myelodysplastic Syndromes 62 Paraplatin ® 62 nasal polyposis 62 beta 1a 62 candidemia 62 dual endothelin receptor antagonist 62 primary immunodeficiency PI 62 chronic myeloid 62 panobinostat 62 castrate resistant 62 Flu Cy 62 Elevated serum 62 T2DM 62 lymphoproliferative disorders 62 Relapsed Refractory 62 miglustat 62 Toxicities 62 adenomatous polyps 62 Radioimmunotherapy 62 presymptomatic 62 Fibroblast 62 FUS1 62 EGFR mutation positive 62 extramedullary 62 Pegylated Liposomal Doxorubicin 62 cellularity 62 Hematopoietic 62 chemosensitivity 62 HLA DRB1 * 62 papillary carcinoma 62 paraneoplastic 62 SIADH 62 β blockers 62 Cystatin C 62 extracapsular extension 62 Parathyroid Hormone 62 cystectomy 62 Gleevec resistant 62 p# antigen 62 smoldering multiple myeloma 62 polyposis 62 benign prostatic hypertrophy BPH 62 prostate cancer HRPC 62 FDG PET imaging 62 myeloid metaplasia 62 metastatic renal 62 GH deficiency 62 underwent radical cystectomy 62 cinacalcet 62 antiproliferative effects 62 immunodeficiency disorders 62 Prostatic 62 depsipeptide 62 LRAT 62 choriocarcinoma 62 Chronic Myeloid Leukemia CML 62 gene polymorphisms 62 mCRC patients 62 clinico pathological 62 PEG IFN 62 renal allograft 62 endoscopic ultrasonography 62 fibrosarcoma 62 Subgroup analysis 62 cytogenetic abnormalities 62 somatostatin receptor 62 pathologic diagnosis 62 node metastasis 62 HER2 amplification 62 interferon IFN 62 verteporfin 62 Subtypes 62 myeloproliferative disorder 62 chemoradiotherapy 62 Acute Renal Failure 62 myxoid 62 transplantation HSCT 62 orchitis 62 KRAS oncogene 62 CsA 62 primary aldosteronism 62 BCR ABL mutations 62 PHPT 62 atypical hyperplasia 62 hematologic toxicity 62 Asymptomatic 62 murine model 62 prognostic factor 62 serum urate levels 62 idiopathic membranous nephropathy 62 Pathway Inhibitor 62 Angiotensin converting enzyme 62 cyclin E 62 hormone receptor negative 62 neovascularisation 62 histologically 62 Anaplastic 62 nonischemic 62 HLA DR4 62 Neoadjuvant 62 autologous transplantation 62 uricase 62 concurrent chemoradiation 62 MYCN amplification 62 TRAIL R1 62 MALT lymphoma 62 epoetin alpha 62 nodal metastases 62 preoperative PSA 62 prostate cancer CRPC 62 Tyrosine Kinase Inhibitor 62 nonnucleoside reverse transcriptase inhibitors 62 vWF 62 renal cortical 62 cutaneous melanoma 62 LHRH agonists 62 cholelithiasis 62 Neoplasms 62 p# Shc 62 locoregional 62 sJIA 62 hematological parameters 62 PSADT 62 leukoencephalopathy 62 tigecycline 62 ductal adenocarcinoma 62 Malignancies 62 metastatic renal cell 62 noncalcified 62 busulfan 62 lymphocytic 62 lymphomas leukemias 62 small molecule activators 62 C. trachomatis 62 carcinoids 62 epithelial ovarian 62 neoplasia CIN 62 Vidaza azacitidine 62 immunocompetent 62 lung carcinomas 62 skeletal metastases 62 thiopurine 62 FUSILEV enhances 62 Invasive Breast Cancer 62 castration resistant prostate cancer 62 pathophysiological effects 62 mutated KRAS gene 62 EGFR TKI 62 nucleoside analog 62 Metastatic Prostate Cancer 62 neurogenic bladder 62 oesophageal adenocarcinoma 62 alkylating 62 systemic amyloidosis 62 Circulating tumor cells 62 adrenalectomy 62 chemoembolization 62 bone metastasis 62 neoplasia 62 immunohistochemical staining 62 Dysregulation 62 Hormone Refractory Prostate Cancer 62 essential thrombocythemia ET 62 Antitumor Activity 62 dasatinib Sprycel 62 PEGylated anti 62 neoadjuvant chemotherapy 62 SCIg 62 refractory cutaneous T 62 Chronic Lymphocytic Leukemia CLL 62 CD# + [001] 62 Hyperlipidemia 62 elevated ALT 62 advanced neoplasia 62 androgen ablation 62 median survivals 62 TRAIL R2 62 Lung transplantation 62 thyrotropin 62 Antiangiogenic 62 tumor lysis syndrome 62 epithelial ovarian cancer 62 alpha1 antitrypsin deficiency 62 HBsAg 62 histological diagnosis 62 N. gonorrhoeae 62 Nonspecific 62 amisulpride 62 pulmonary hypertension PH 62 neutropenic patients 62 hyperplastic 62 Castration Resistant Prostate Cancer 62 lymphoid cells 62 medullary thyroid carcinoma 62 nondiabetic patients 62 radiosensitivity 62 Polymorphisms 62 Radical prostatectomy 62 mutated KRAS 62 plasminogen activators 62 ECOG PS 62 advanced hepatocellular carcinoma 62 neoplastic lesions 62 flutamide 62 curative resection 62 metastatic castration resistant 62 sonographic diagnosis 62 Cytogenetic 62 SHPT 62 isoenzyme 62 postoperative radiotherapy 62 cervical lesions 62 relapsed leukemia 62 patientswith 62 PDGFR alpha 62 Azacitidine 62 achieved CCyR 62 rhGH 62 selectively inhibited 62 compound AEZS 62 invasive lobular carcinoma 62 BARACLUDE ® 62 HBeAg + 62 baseline LDH 62 caspofungin 62 carcinoid tumor 62 hepatic arterial 62 antithymocyte globulin 62 riociguat 62 HER2 receptor 62 hamartomas 62 macrolide antibiotic 62 multivariate analyzes 62 estramustine 62 IV NSCLC 62 GIST tumors 62 intracranial hemorrhage ICH 62 HLA DQ2 62 geographic atrophy 62 mesangial 62 Prognostic factors 62 Upregulation 62 interleukin IL -# 62 #F FDG 62 erythropoietic 62 Candida infection 62 invasive carcinomas 62 monoclonal anti 62 AZT zidovudine Retrovir 62 tumorigenicity 62 malignant ovarian 62 eculizumab therapy 62 Hepatocellular Carcinoma 62 gadolinium enhanced 62 precursor lesions 62 paricalcitol 62 recombinant FSH 62 Thal Dex 62 #F FDG PET 62 mCRPC 62 Malignant Melanoma 62 acute myelogenous leukemia AML 62 BRAF V#E 62 Pim kinases 61 Vascugel 61 remission induction 61 CDK inhibitor 61 antiandrogens 61 TTR gene 61 cervical lymph nodes 61 osteosarcomas 61 Cystectomy 61 urinary N telopeptide 61 intravesical therapy 61 humoral responses 61 postoperative chemotherapy 61 atrophic vaginitis 61 histopathological 61 renal pelvis 61 metastatic lesion 61 recurrent metastatic 61 overt hypothyroidism 61 Pegylated interferon 61 ADAMTS# 61 androgen deficiency 61 ANCA associated 61 neuritic 61 oral Hycamtin 61 enteroviral infection 61 normal karyotype 61 receptor blocker 61 immunoreactivity 61 paroxysmal nocturnal hemoglobinuria 61 histopathologic examination 61 gemcitabine Gemzar 61 lymphocytic leukemia 61 PSA nadir 61 cisplatin chemotherapy 61 thymectomy 61 HQK 61 Diabetic Neuropathy 61 treat benign prostatic 61 adenomyosis 61 TNF blocker therapy 61 Peginterferon 61 gastrointestinal stromal tumor 61 Lymph node 61 C#BL 6 mice 61 breast cancer subtypes 61 pamidronate 61 ischemic lesions 61 TNF alpha selectively neutralizing 61 Interferon Beta 61 Temsirolimus 61 aMCI precursor 61 Metastatic Renal Cell Carcinoma 61 chronic granulomatous disease 61 cancer mCRC 61 anthracyclines taxanes 61 antioxidant supplementation 61 mL/min/#.# m 2 61 ertapenem 61 rifamycins 61 hypermethylated 61 PAOD 61 amenorrhoea 61 tumor infiltrating lymphocytes 61 cytologically confirmed 61 IDH1 mutation 61 Mutational 61 colony stimulating factor 61 echocardiographic parameters 61 acute lymphoblastic 61 TOP2A 61 Systemic Sclerosis 61 RhuDex R 61 AGTR1 61 angiographically 61 malignant neoplasm 61 demyelinating 61 atypical Hemolytic Uremic Syndrome 61 sacral neuromodulation 61 Acute Myelogenous Leukemia AML 61 haematologic malignancies 61 etiologic 61 hemorrhagic cystitis 61 Hcy 61 immunosuppressive regimen 61 GSTP1 61 Dasatinib 61 bioavailable testosterone 61 Bortezomib 61 Anthracycline 61 receiving VICTRELIS 61 juvenile idiopathic arthritis JIA 61 Dilated Cardiomyopathy 61 bullous 61 anthracycline containing 61 follicular lymphomas 61 coinfection 61 Lupus Nephritis 61 Vidaza ® 61 neurocognitive impairment 61 pyrimethamine 61 Myelodysplastic Syndrome 61 Combination therapy 61 atherothrombotic 61 FluCAM arm 61 hepatocellular carcinoma 61 Aurora Kinase 61 stage IIIb IV 61 biochemical abnormalities 61 intestinal mucosal 61 FLT3 61 efalizumab 61 metastatic RCC 61 phosphorylated tau 61 Chronic Sinusitis 61 keloid scarring 61 PTLD 61 serum albumin 61 CIMZIA TM certolizumab pegol 61 interferon beta therapy 61 anaplastic astrocytomas 61 mg/m2 dose 61 micrometastasis 61 medullary thyroid cancer 61 pseudotumor 61 bronchoalveolar lavage BAL 61 HER2 positive cancers 61 Peritoneal 61 Xanafide 61 chronic idiopathic 61 lung adenocarcinomas 61 carcinoid 61 metabolomic profiles 61 uPA 61 PBMCs 61 Choroidal 61 Histologically 61 hMG 61 cis retinoic acid 61 minimally symptomatic 61 Non Alcoholic Fatty 61 debulking surgery 61 dacarbazine DTIC 61 polycythemia vera PV 61 Retinoic Acid 61 aspartate aminotransferase AST 61 PsA 61 Carcinoma 61 B7 H3 61 imatinib therapy 61 Atherosclerotic 61 RezularTM 61 bacteriuria 61 myelomas 61 eosinophil count 61 kidney allograft 61 lymphopenia 61 immune modulating 61 detectable HCV RNA 61 pheochromocytomas 61 pretreatment serum 61 leukocyte count 61 Diabetic nephropathy 61 elevated triglyceride levels 61 TMPRSS2 ERG 61 CCyR 61 replicase 61 hormone refractory 61 childhood acute lymphoblastic 61 acute leukemias 61 bronchoalveolar 61 imatinib Gleevec 61 urine cytology 61 follicular thyroid cancer 61 International Prognostic Scoring 61 prostate carcinomas 61 histone deacetylase inhibitor 61 Hypertrophic 61 PNH patients 61 HLA A2 61 latent tuberculosis infection 61 serum TSH 61 fluconazole resistant 61 Tumor Necrosis Factor 61 PROSTVAC VF 61 cytogenic 61 Degarelix 61 cardiotoxic 61 MCyR 61 lamivudine resistant 61 Accelerated Partial Breast Irradiation 61 dimeric 61 IV bisphosphonates 61 lymphovascular invasion 61 Renal Cell Carcinoma 61 anterior uveitis 61 eosinophilic asthma 61 pericardial effusion 61 PTPN# 61 secondary amenorrhea 61 statistically significant p = 61 lysosomal storage disease 61 allogeneic bone marrow 61 SLNB 61 adriamycin 61 acute aortic dissection 61 EGFR tyrosine kinase inhibitors 61 Waldenstrom macroglobulinemia 61 nonsmall cell lung cancer 61 TET2 61 pain palliation 61 recurrent GBM 61 resected pancreatic cancer 61 pegylated IFN 61 Adenocarcinoma 61 PEGylated Fab fragment 61 tryptase 61 leukemia CLL 61 HRCT 61 mononuclear 61 refractory chronic lymphocytic 61 subcutaneous immunoglobulin 61 pharmacologic intervention 61 thyrotoxicosis 61 nephron sparing surgery 61 effector function 61 octreotide LAR 61 decitabine 61 phenothiazines 61 deep venous thromboses 61 antibody titer 61 anemia hemoglobin 61 nonalcoholic steatohepatitis 61 resistant hormone refractory 61 glomerular 61 Sipuleucel T 61 anal intraepithelial neoplasia 61 orally administered inhibitor 61 immunopathology 61 hyper IgE syndrome 61 Inhaled nitric oxide 61 thyroid nodules 61 Hepatocellular Carcinoma HCC 61 selective modulator 61 cryptogenic 61 papillary thyroid carcinoma 61 atherogenic dyslipidemia 61 prognostic marker 61 lymphoid malignancies 61 Myelodysplasia 61 mucosal inflammation 61 Ischemic 61 hypoperfusion 61 adrenocortical 61 nephrotoxicity 61 VEGFR1 61 endoscopic resection 61 viral kinetics 61 seminal vesicle invasion 61 hypomethylating agent 61 underwent radical prostatectomy 61 neoplasms 61 karyotypes 61 heavily pretreated 61 Diffuse Large B 61 BRCA1 mutation carriers 61 lanthanum carbonate 61 azacytidine 61 Endometrial Cancer